Analyst Price Target is $6.00
▲ +142.91% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Avenue Therapeutics in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 142.91% upside from the last price of $2.47.
Current Consensus is
The current consensus among 1 contributing investment analysts is to hold stock in Avenue Therapeutics. This rating has held steady since October 2019, when it changed from a Buy consensus rating.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.